Literature DB >> 27989141

No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.

Lee Faulkner1, Xiaoli Meng1, Dean J Naisbitt1, Colin F Spraggs2, B Kevin Park1.   

Abstract

It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells. However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury revealed no evidence for drug-specific activation. T cells were exposed to lapatinib, the M11 aldehyde, and quinone imine [oxidized form of hydroquinone amine M1] metabolites. Reactivity of the quinone imine was confirmed by mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27989141     DOI: 10.1021/acs.chemrestox.6b00400

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  2 in total

1.  T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.

Authors:  Tina Rubic-Schneider; Masataka Kuwana; Brigitte Christen; Manuela Aßenmacher; Otmar Hainzl; Frank Zimmermann; Robert Fischer; Vera Koppenburg; Salah-Dine Chibout; Timothy M Wright; Andreas Seidl; Michael Kammüller
Journal:  Blood Adv       Date:  2017-02-09

Review 2.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.